3.4.22.26	evolution	cancer procoagulant belongs to cysteine proteinase superfamily	753332	
3.4.22.26	physiological function	cancer procoagulant (CP) is a protease present in malignant tumours, but not normal tissue, is a known activator of coagulation factor X (FX). degradation of FX by CP occurs at a much slower rate than degradation by conventional activators. Cancer procoagulant has a function in cancer progression. The enzyme is not essential for either cancer-associated blood coagulation or the degradation of extracellular matrix proteins. The protease may be required for the proteolytic activation of membrane receptors	755322	
3.4.22.26	physiological function	cancer procoagulant directly activates blood coagulation factor X in absence of activated factor VII. Cancer procoagulant is described in malignant and fetal, but not in normally differentiated tissues. Cancer procoagulant has proadhesive properties together with factor X-activating activity	753332	
3.4.22.26	physiological function	cancer procoagulant increases the expression of L1 cell adhesion molecule (L1CAM) mRNA and VEGF in MCF-7 breast cancer cells and E14 mouse embryonic stem cells	733446	
3.4.22.26	physiological function	cancer procoagulant increases the steady-state mRNA level of angionin in MCF-7 breast cancer cells but decreases the expression of VEGF	733446	
3.4.22.26	physiological function	cancer procoagulant is a direct activator of coagulation factor X, itt is among one of the tumour cell products or activities which may promote fibrin formation and is suggested to be selectively associated with the malignant phenotype	755327